Novo Nordisk
-
Novo Nordisk expands programme to reach 20,000 children with diabetes in developing countries
Nov 16, 2016News Hour: Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees... -
Novo Nordisk announces plans to reduce workforce
Sep 29, 2016News Hour: Novo Nordisk has today announced its intention to reduce its workforce by approximately 1,000 employees of the 42,300 positions in the company’s global organization. This is one of the several actions taken to reduce... -
Novo Nordisk to ax 1,000 jobs in cost-cutting drive
Sep 29, 2016The world’s largest insulin maker, Novo Nordisk, is cutting 1,000 jobs as a part of a plan to reduce costs as it faces a challenging environment in 2017, especially in the large U.S. market, the company... -
NovoRapid® receives positive CHMP opinion for extended use in children as young as one year old
Sep 20, 2016News Hour: Novo Nordisk announced that the Committee for Medicinal Products for Human Use, CHMP, has adopted a positive opinion to extend the use of NovoRapid® (insulin aspart) in the European Union for children with diabetes... -
Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia
Sep 15, 2016News Hour: Novo Nordisk presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly greater for Xultophy® (IDegLira) compared to up-titration with insulin glargine U100 in adults... -
Lars Rebien Sørensen to retire as CEO of Novo Nordisk
Sep 3, 2016News Hour: Novo Nordisk A/S today announced that Lars Rebien Sørensen, president and chief executive officer, will retire from the company by the end of 2016. Lars Fruergaard Jørgensen, currently executive vice president and head of...
